Diseases requiring painless gastroenteroscopy examination include abdominal pain, hematochezia, anemia, gastrointestinal tumors, esophageal foreign bodies and other related conditions.
Conditions
Interventions
R1 Group:Remimazolam 0.10 mg/kg was administered, followed by propofol at the corresponding dose to initiate the sequential trial.
R2 Group:Remimazolam 0.20mg/kg was administered, followed by propofol at the corresponding dose to initiate the sequential trial.
R3 Group:Remimazolam 0.2mg/kg was administered, followed by propofol at the corresponding dose to initiate the sequential trial.
R5 Group:Remimazolam 0.30mg/kg was administered, followed by propofol at the corresponding dose to initiate the sequential trial.
R4 Group:Remimazolam 0.25mg/kg was administered, followed by propofol at the corresponding dose to initiate the sequential trial.
Sponsors
Hebei General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18–65 years, BMI 18–30 kg/m^2; 2.ASA physical status II–III; 3. Patients scheduled for painless gastrointestinal endoscopy; 4.Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiac, hepatic, renal or pulmonary dysfunction; 2. Patients with a preoperative history of alcoholism, opioid abuse or abuse of other sedatives; 3. Patients with upper respiratory tract infection within 2 weeks, difficult airway (Mallampati classification >= Grade III) or obstructive sleep apnea syndrome;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 50% effective dose,ED50;95% effective dose,ED95;95%confidence interval,95%CI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean Arterial Pressure (MAP);Bispectral Index(BIS);Heart Rart;Peripheral Oxygen Saturation(SpO2); | — |
Countries
China
Contacts
Public ContactYue Lihui
Hebei General Hospital
Outcome results
None listed